UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia

Phase 1 Recruiting 9 enrolled Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to explore the safety and efficacy of UCMSC-Exo in consolidation chemotherapy-induced myelosuppression in patients with acute myeloid leukemia after achieving complete remission.

Timeline

Start: 2025-02-26
Primary completion: 2026-02
Completion: 2027-02

Publications

Wu D, He W, He J, Wu Y, Chen W, Zhang J, Yang S, Tan Y, Chen Z, Li Q. UCMSC-Exo for chemotherapy-induced myelosuppression in acute myeloid leukemia: a phase I clinical trial protocol. Nanomedicine (Lond). 2026 Jun 25:1-11. doi: 10.1080/17435889.2026.2692455. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	UCMSC-Exo	Other / unclassified	—	Intravenous

UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia

Summary

Timeline

Publications

Drugs

Indications